It's a sorry case when the Bears can jump on something like this without all the info. Just a rambling thought on the matter because of the influence this has had on the share price.
I think RCPI offered the sale of shares before after a private placement, who knows if the shares were actually sold, but, they filed the form to provide the means to make the offering. Anyway, if the shares are sold it just adds to the dilution...
The scientist need to score a big deal with a big pharma to get things moving ahead and out of all this, yes?
From the news release...
"...Quotient Clinical, the Company's UK-based outsourced partner will immediately begin recruitment of healthy volunteers, with dosing to commence in February 2015, and with initial formulation PK data to emerge shortly after. Although study data management and analysis are expected to continue into August 2015, the Company anticipates having a substantial amount of data by mid-year. As previously disclosed, Quotient Clinical will employ its RapidFACT® (Rapid Formulation development And Clinical Testing) service to accelerate the development of these novel, oral, modified release formulations that have been co-developed between the two companies..."
We should be seeing an increasing share value, don't you think?
To move to Phase I trials would be a positive movement forward. It's a part of the process and should increase the intellectual property value, yes? There is a certain amount of confidence of the process because of the prior study outcomes and it should have a positive affect on the share price, yes?
So, we should see a rising value of the intellectual property as the CTA and IND process moves on and so should the share price be affected?...
The next leg up may be a big one considering news may be coming concerning the CTA process. It'll be news of accomplishment rather than just timeline stuff.
8K says Mr Dent from RCPI's Board of Directors will be replacing the retiring Park Dodd III as the Company's new Chief Financial Officer and Vice President of Operations and also serve as the Company's Secretary and Treasurer. RCPI will be looking to fill the Mr. Dent's vacated position on the Board.
Dr Mullan said in his presentation that one of the objectives of Phase 1 would be to show that the RCPI Anatabine Citrate reduces the propensity of inflammation in the nearby tissue of an inflicted area. Guess this would be a huge advancement to show this.
This is very exciting, Rock Creek Pharmaceuticals is going to Webcast their Presentation at the Biotech Showcase™ 2015 in San Francisco on Monday, January 12th, at 4:00PM PT (7:00 PM ET).
The press release says "Dr. Mullan will outline the Company's regulatory strategy and ongoing drug development initiatives designed to advance its lead molecule into phase I and phase II trials."
It also says "Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will present preclinical and clinical data for anatabine citrate, a small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics."
And press release says an archived version of the webcast will be available two hours following the presentation and can be accessed within the investors' section of the Rock Creek Pharmaceuticals website.